Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Androgen receptor (AR)-directed therapy is a cornerstone treatment for prostate cancer.
• Resistance to AR-directed therapy is a significant clinical challenge.
• Epithelial plasticity, leading to neuroendocrine features and low AR expression, is an emerging resistance mechanism.

Purpose of the Study:

• To investigate the molecular basis of treatment-resistant prostate cancer with neuroendocrine features.
• To understand the relationship between adenocarcinoma and neuroendocrine prostate cancer subtypes.
• To explore the role of epigenetics in the development of treatment resistance.

Main Methods:

• Whole-exome sequencing of metastatic prostate cancer biopsies.
• Longitudinal analysis of biopsy samples from the same patients.
• Genome-wide DNA methylation analysis.

Main Results:

• Significant genomic overlap was observed between castration-resistant prostate adenocarcinoma (CRPC-Adeno) and neuroendocrine prostate cancer (CRPC-NE).
• Divergent clonal evolution is a likely model for the development of these resistant subtypes.
• Marked epigenetic differences exist between CRPC-NE and CRPC-Adeno, suggesting a role for epigenetic modifiers.

Conclusions:

• Treatment resistance in advanced prostate cancer can emerge via an 'AR-indifferent' cell state.
• Divergent clonal evolution contributes to the development of alternative cell states.
• Epigenetic alterations may drive the transition to treatment-resistant neuroendocrine prostate cancer.